• Home
• Responsibility
• CR Report 2004
• Engagement with stakeholders

Engagement with stakeholders

Engaging with the different groups that have an interest in the way GSK operates is an important part of responsible business practice. These stakeholders include employees, investors, patients, doctors, governments and NGOs. By listening to them and being open about our views and actions we can build trust and address their concerns.

Much of this discussion takes place in the normal course of business. For example our scientists meet regularly with academics, researchers and other pharmaceutical companies as part of their work. Through our access to medicine programmes and community investment we collaborate closely with NGOs, multilateral agencies, governments and community groups. More information is available on stakeholder consultation in the following sections: Access to medicines, animal research, EHS management, leadership and advocacy, and suppliers.

We interact with governments to give our views on policy issues affecting GSK and the pharmaceutical industry. We engage with governments directly or through membership of trade organisations, such as the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Association of the British Pharmaceutical Industry (ABPI). Our size and global reach give us access to policy makers and we recognise that we need to use this responsibly to benefit patients and our business. More information on our approach to external relations is available at External Affairs.

We also meet with some stakeholders specifically to discuss corporate responsibility issues. Their feedback informs our approach to managing and reporting on these subjects.

This section focuses on our CR engagement. It covers our activities in 2004 including:

• Our CR survey of key stakeholders
• Engagement with socially responsible investment analysts

Back to top